1. Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy

   • Samantha K. Korver
   • Rachel J. Gibson
   • Janet K. Coller

   Review Article 24 November 2018 Pages: 217 - 236

   

2. 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability

   • Shengnan Du
   • Jeffrey G. Sarver
   • William A. Maltese

   Original Article 13 November 2018 Pages: 237 - 254

   

3. Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines

   • Ajimu Keremu
   • Abudusaimi Aimaiti
   • Xiaoguang Zou

   Original Article 14 November 2018 Pages: 255 - 264

   

4. Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals

   • Gordon T. Bolger
   • Albert Licollari
   • Peter P. Sordillo

   Original Article 14 November 2018 Pages: 265 - 275

   

5. Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B

   • Shuqi Chi
   • Yan Liu
   • Hongbo Wang

   Original Article 15 November 2018 Pages: 277 - 287

   

6. A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors

   • Masanori Toyoda
   • Koichiro Watanabe
   • Hironobu Minami

   Original Article Open access 16 November 2018 Pages: 289 - 299

7. Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project

   • Marina E. Cazzaniga
   • E. Ciruelos
   • on behalf of the MACBETH Group

   Original Article 20 November 2018 Pages: 301 - 318

   

8. Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

   • Renu Singh
   • Shailly Mehrotra
   • on behalf of the ETCTN-6745 study team

   Original Article 20 November 2018 Pages: 319 - 328

   

9. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin^®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors

   • Angelica L. Quartino
   • Hanbin Li
   • Bert Lum

   Original Article Open access 22 November 2018 Pages: 329 - 340

   

10. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia

    • Sanjeev Khera
    • Amita Trehan
    • Neelam Varma

    Original Article 24 November 2018 Pages: 341 - 348

    

11. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities

    • Jennifer H. Foster
    • Patrick A. Thompson
    • Eric S. Schafer

    Original Article 28 November 2018 Pages: 349 - 360

    

12. Murine RAW264.7 cells as cellular drug delivery carriers for tumor therapy: a good idea?

    • Huangliang Zheng
    • Jiaqi Li
    • Yihui Deng

    Original Article 30 November 2018 Pages: 361 - 374

    

13. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study

    • Marianne Pavel
    • Françoise Borson-Chazot
    • Diego Ferone

    Original Article 08 December 2018 Pages: 375 - 385

    

14. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion

    • Abeer F. Alharbi
    • Robert A. Kratzke
    • Mark N. Kirstein

    Short Communication 12 December 2018 Pages: 387 - 391